Why Biotech Boomer Intercept Pharmaceuticals, Inc. Tumbled Again

Before you go, we thought you'd like these...
Before you go close icon

High-flying biotech Intercept Pharmaceuticals enjoyed a 516% gain last week, but shares have tumbled this week. After yesterday's 18% dive, shares dropped another 30% today. In the following video, analyst Max Macaluso discusses what caused today's drop and the key issues that long-term investors need to focus on.

Stock picks for the ultimate growth portfolio
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

The article Why Biotech Boomer Intercept Pharmaceuticals, Inc. Tumbled Again originally appeared on Fool.com.

Max Macaluso, Ph.D., owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences and Johnson & Johnson and also owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

People are Reading